Background
==========

*CDH1*germline mutations are associated with the development of the autosomal cancer syndrome namely Hereditary Diffuse Gastric Cancer (HDGC) \[[@B1],[@B2]\]; about 25-30% of families fulfilling the clinical criteria for HDGC established by the International Gastric Cancer Linkage Consortium (IGCLC) have constitutional alterations of the *CDH1*gene \[[@B3]\]. *CDH1*germline mutations can also be identified in sporadic early onset GC (EOGC) in less than 4% of patients 35 years of age at the time of diagnosis, presenting as *de novo*mutations \[[@B4]\].

Different patterns of *CDH1*germline mutations have been described as truncating, deletion, insertion, splice site, non sense, silence, and at last, missense alterations \[[@B5]\].; for *CDH1*non-missense mutations, the penetrance rate is high, with an estimated risk of \> 80% \[[@B3]\]., in missense mutation carriers, the estimated cancer-risk is unknown. *CDH1*missense mutations are rather frequently detected in HDGC and in EOGC, and they can be classified as neutral or pathogenic variants \[[@B6]\].

The worldwide incidence of gastric carcinoma is extremely heterogeneous and the causes of these differences are still unclear; it has been reported that GC presents different characteristics considering tumors coming from low- and high-risk area \[[@B7]\]. In GC patients coming from high-risk areas environmental factors, as specific foods, are more probably associated with the gastric carcinogenesis \[[@B8],[@B9]\] in which genetic factors, as *CDH1*or *TP53*germline mutations, are very rarely identified \[[@B10]-[@B15]\]. To assess the *CDH1*germline mutation frequency in low- and high-risk areas for GC, we reviewed all E-cadherin constitutional alterations identified from 1998 to date, considering the worldwide geographic distribution. We focused on low- and high-risk areas of gastric carcinoma in particular.

Methods
=======

Study accuracy and approach
---------------------------

The accuracy of this systematic review and meta-analysis was assessed using the checklist of items in accordance with the \"Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement\" \[[@B16]\].

In particular, we scheduled this systematic review and meta-analysis as follows: a) Identification: to assess the *CDH1*germline mutation frequency in different risk areas for GC; b) Screening: to search all identified *CDH1*germline mutations, as well as in patients with DGC as in asymptomatic carriers; c) Eligibility: to include all data reported in an accessible source bank (the National Library of Medicine\'s MEDLINE database); d) Included: to analyse the obtained results with statistical analysis (Figure [1](#F1){ref-type="fig"}).

![**Flow diagram of study selection and information through different phases of the systematic review and meta-analysis**. (The diagram was structured in accord with the Digestive Disease Week; United European Gastroenterology Week and with the PRISMA statement)](1471-2407-12-8-1){#F1}

Study population
----------------

In this study we considered all countries in which an independent *CDH1*genetic screening has been performed, aiming for germline mutation search.

We subdivided the world areas in two groups: low (group A) and middle-high incidence (group B) areas, considering the GC incidence data reported by Ferlay J. and Colleagues \[[@B17]\]. Among group A, we identified these countries: USA, Spain, France, Ireland, Canada, United Kingdom, New Zealand, Germany, Finland, Pakistan, Sweden, the Netherlands, Austria and Iran. This group also included some cases defined only as \"European\" and without specific ancestry. We excluded that this part is comes from the European area with middle-high GC risk (as North of Portugal, Central Italy, and Eastern Europe). Group B includes these zones: Italy (Tuscany), Portugal (North), Japan, China, Korea, South America, Lithuania and Poland.

CDH1 germline mutation search and selected articles
---------------------------------------------------

We revised all *CDH1*germline mutations reported in MEDLINE from March 1998 to November 2010, through analysis of original reports and reviews of the literature edited in the English language. Moreover, we also included data from two international workshops of the IGCLC (in 1999 and in 2010) \[[@B2],[@B3]\]. Whenever sufficient, we also considered information obtained from abstract in the English language with the main text edited in other languages; a total of 156 papers were selected for this study. The reported *CDH1*constitutional alterations are defined as truncating, deletion, insertion, splice site, non-sense, and missense mutations (Table [1](#T1){ref-type="table"}); we grouped these mutations as *non-missense*(truncating, deletion, insertion, splice site and non sense) or *missense*mutations. This study excluded all *CDH1*somatic mutations identified in gastric carcinoma, and the germline alterations found in primary lobular breast carcinoma as well as in mucinous colon cancer. We considered also mutations namely in review papers as \"unpublished results\" \[[@B5],[@B18]\].

###### 

*CDH1*germline mutations detected to date

  Reference                  *CDH1*mutation                  Exon/Intron   Mutation Type          Ancestry
  -------------------------- ------------------------------- ------------- ---------------------- ---------------------------------------
  \[[@B20]\]                 5\'UTR(-117)G \> A              Promotor      5\'UTR substitution    USA (1)
  \[[@B20]\]                 5\'UTR(-71)C \> G               Promotor      5\'UTR substitution    USA (1)
  \[[@B4]\]                  -63 C \> A                      Promotor      5\'UTR substitution    Italy (1)
  \[[@B21]\]                 Del 5\'UTR-ex 1                 Promotor      Deletion               Spain (1)
  \[[@B21]\]                 del ex 1-2                      Exon 1-2      Deletion               Ireland (1), Canada (1) Lithuania (1)
  \[[@B5]\]                  2 T \> C                        Exon 1        Missense               Unknow (1)
  \[[@B22]\]                 3 G \> C                        Exon 1        Nonsense               Canada (1)
  \[[@B20]\]                 41delT                          Exon 1        Deletion               USA (1)
  \[[@B23]\]                 45insT                          Exon 1        Insertion              UK (1)
  \[[@B5]\]                  46insTGC                        Exon 1        Insertion              Unknow (1)
  \[[@B20]\]                 48 + 5 G \> C                   Intron 1      Splice Site            USA (1)
  \[[@B20]\]                 48 + 15 C \> G                  Intron 1      Splice Site            USA (1)
  \[[@B18],[@B24],[@B25]\]   49-2A \> G                      Intron 1      Splice Site            Europe (1), UK (1), Ireland (1)
  \[[@B26]\]                 53delC                          Exon 2        Deletion               Europe (1)
  \[[@B24]\]                 59 G \> A                       Exon 2        Non sense              UK (1)
  \[[@B27]\]                 70 G \> T                       Exon 2        Non sense              USA (1)
  \[[@B28]\]                 185 G \> T                      Exon 3        Missense               Japan (1)
  \[[@B29]\]                 187 C \> T                      Exon 3        Non sense              USA (1)
  \[[@B1]\]                  190 C \> T                      Exon 3        Non sense              New Zealand (1)
  \[[@B30]\]                 283 C \> T                      Exon 3        Non sense              France (1)
  \[[@B18]\]                 353 C \> G                      Exon 3        Missense               Europe (1)
  \[[@B31]\]                 372delC                         Exon 3        Deletion               Germany (1)
  \[[@B32]\]                 377delC                         Exon 3        Deletion               Unknow (1)
  \[[@B33]\]                 382delC                         Exon 3        Deletion               Europe (1)
  \[[@B20]\]                 388 + 26 C \> T                 Intron 3      Splice Site            USA (1)
  \[[@B32]\]                 515 C \> G                      Exon 4        Missense               Unknown (1)
  \[[@B34]\]                 525 C \> G                      Exon 4        Missense               Finland (1)
  \[[@B6]\]                  532-18 C \> T                   Intron 4      Splice site            UK (1), Portugal (1)
  \[[@B27]\]                 586 G \> T                      Exon 5        Non sense              Europe (1)
  \[[@B33]\]                 531 + 1 G \> A                  Intron 5      Splice site            Europe (1)
  \[[@B35]\]                 531 + 2 T \> A                  Intron 5      Splice site            France (1)
  \[[@B36]\]                 641 T \> C                      Exon 5        Missense               Europe (1)
  \[[@B4]\]                  670 C \> T                      Exon 5        Missense               Italy (1)
  \[[@B18]\]                 715 G \> A                      Exon 6        Missense               Europe (1)
  \[[@B37]\]                 731A \> G                       Exon 6        Missense               Korea (1)
  \[[@B5]\]                  753insG                         Exon 6        Insertion              Unknown (1)
  \[[@B32]\]                 808 T \> G                      Exon 6        Missense               Unknown (1)
  \[[@B23]\]                 832 G \> A                      Exon 6        Splice site            Pakistan (1)
  \[[@B38]\]                 833-2A \> G                     Inton 6       Splice site            USA (1)
  \[[@B33]\]                 892 G \> A                      Exon 7        Missense               Europe (1)
  \[[@B22],[@B39]\]          1003 C \> T                     Exon 7        Non sense              Sweden (1), Canada (2)
  \[[@B1]\]                  1008 G \> T                     Exon 7        Splice site            New Zealand (1)
  \[[@B23],[@B40]\]          1018A \> G                      Exon 8        Missense               Europe (1), China (1)
  \[[@B5]\]                  1023 T \> G                     Exon 8        Nonsense               Unknown (1)
  \[[@B22]\]                 1063delT                        Exon 8        Deletion               Canada (1)
  \[[@B33]\]                 1064insT                        Exon 8        Insertion              UK (1)
  \[[@B18]\]                 1107delC                        Exon 8        Deletion               Spain (1)
  \[[@B41]\]                 1118 C \> T                     Exon 8        Missense               Italy (1)
  \[[@B33],[@B42]\]          1134del8ins5                    Exon 8        Deletion/Insertion     Netherlands (1)
  \[[@B18],[@B35]\]          1137 G \> A                     Exon 8        Splice site            Europe (2)
  \[[@B27]\]                 1137 + 1 G \> A                 Intron 8      Splice site            USA (1)
  \[[@B33],[@B43]\]          1212delC                        Exon 9        Deletion               Europe (1), USA (1)
  \[[@B33]\]                 1226 T \> C                     Exon 9        Missense               Europe (1)
  \[[@B44]\]                 1243A \> C                      Exon 9        Missense               Japan (1)
  \[[@B22]\]                 1285 C \> T                     Exon 9        Missense               Canada (1)
  \[[@B33]\]                 1226 T \> C                     Exon 9        Missense               Europe (1)
  \[[@B45]\]                 1306_1303insA, 1306_1307delTT   Exon 9        Del/Ins                Austria (1)
  \[[@B18]\]                 1391-1392delTC                  Exon 10       Deletion               Europe (1)
  \[[@B37]\]                 1460 T \> C                     Exon 10       Missense               Korea (1)
  \[[@B46]\]                 1466insC                        Exon 10       Insertion              UK (1)
  \[[@B23]\]                 1472insA                        Exon 10       Insertion              UK (1)
  \[[@B33]\]                 1476delAG                       Exon 10       Deletion               Europe (1)
  \[[@B27]\]                 1487del7                        Exon 10       Deletion               New Zealand (1)
  \[[@B47]\]                 1507 C \> T                     Exon 10       Non sense              China (1)
  \[[@B26]\]                 1565 + 1 G \> T                 Intron 10     Splice site            New Zealand (1)
  \[[@B26]\]                 1565 + 2insT                    Intron 10     Insertion              USA (1)
  \[[@B27]\]                 1588insC                        Exon 11       Insertion              USA (1)
  \[[@B48]\]                 1610delC                        Exon 11       Deletion               Spain (1)
  \[[@B49]\]                 1619insG                        Exon 11       Insertion              Germany (1)
  \[[@B32]\]                 1682insA                        Exon 11       Insertion              Ireland (1)
  \[[@B26]\]                 1710delT                        Exon 11       Deletion               USA (1)
  \[[@B29]\]                 1711insG                        Exon 11       Insertion              USA (1)
  \[[@B33]\]                 1711 + 5 G \> A                 Intron 11     Splice site            Europe (1)
  \[[@B50]\]                 1774 G \> A                     Exon 12       Missense               Sweden (1)
  \[[@B33]\]                 1779insC                        Exon 12       Insertion              Europe (1)
  \[[@B22],[@B26],[@B29]\]   1792 C \> T                     Exon 12       Non sense              UK (1)
  \[[@B32]\]                 1795A \> T                      Exon 12       Missense               Unknown (1)
  \[[@B33]\]                 1779insC                        Exon 12       Insertion              Europe (1)
  \[[@B6]\]                  1849 G \> A                     Exon 12       Missense               USA (2)
  \[[@B32]\]                 1876 T \> A                     Exon 12       Missense               Unknown (1)
  \[[@B6],[@B18],[@B42]\]    1901 C \> T                     Exon 12       Missense/splice site   UK (1), New Zealand (1), Portugal (1)
  \[[@B32]\]                 1913 G \> A                     Exon 12       Nonsense               Spain (1)
  \[[@B20]\]                 1937-13 T \> C                  Intron 12     Splice Site            USA (1)
  \[[@B33]\]                 2061delTG                       Exon 13       Deletion               Europe (1)
  \[[@B38]\]                 2064delTG                       Exon 13       Deletion               USA (1)
  \[[@B1],[@B18]\]           2095 C \> T                     Exon 13       Non sense              New Zealand (1), China (1)
  \[[@B22]\]                 2161 C \> G                     Exon 13       Splice site            Canada (1)
  \[[@B32]\]                 2164 + 5 G \> A                 Exon 14       Splice site            Unknwon (1)
  \[[@B21]\]                 del 14-16                       Ex 14-16      Deletion               Europe (1)
  \[[@B33]\]                 2195 G \> A                     Exon 14       Missense               Europe (1)
  \[[@B32]\]                 2245 C \> T                     Exon 14       Missense               Colombia (1)
  \[[@B51]\]                 2269 G \> A                     Exon 14       Missense               Portugal (1)
  \[[@B52]\]                 2275 G \> T                     Exon 14       Nonsense               Iran (1)
  \[[@B22]\]                 2276delG                        Exon 14       Deletion               Canada (1)
  \[[@B5]\]                  2287 G \> T                     Exon 14       Nonsense               Unknown (1)
  \[[@B26]\]                 2295 + 5 G \> A                 Intron 14     Splice site            Europe (1)
  \[[@B33]\]                 2310delC                        Exon 15       Deletion               Europe (1)
  \[[@B32]\]                 2343A \> T                      Exon 15       Missense               UK (1)
  \[[@B1]\]                  2381insC                        Exon 15       Insertion              New Zealand (1)
  \[[@B32]\]                 2392 G \> A                     Exon 15       Missense               Unknown (1)
  \[[@B38]\]                 2395delC                        Exon 15       Deletion               USA (1)
  \[[@B49]\]                 2396 C \> G                     Exon 15       Missense               Germany (1)
  \[[@B32]\]                 2398delC                        Exon 15       Deletion               Ireland (2)
  \[[@B20]\]                 2439 + 31 G \> A                Intron 15     Splice site            USA (1)
  \[[@B53]\]                 2399delG                        Exon15        Deletion               USA (1)
  \[[@B18]\]                 2440-6 C \> G                   Intron 15     Splice site            Europe (1)
  \[[@B54]\]                 2494 G \> A                     Exon 16       Missense               Japan (1)
  \[[@B21]\]                 Del ex 16                       Exon 16       Deletion               Europe (1)

We used the following search terms to search all reports, reviews and databases: E-cadherin; *CDH1*gene; germline mutation, and genetic screening; HDGC, and IGCLC; familial GC; diffuse histotype; Maori kindred, prophylactic gastrectomy.

Assessment of risk bias
-----------------------

We also evaluated the possibility that the available data is biased; in particular, we considered two kinds of possible bias: a) in case selection, specifically by the literature reviewer and b) from literature data. Point a) was attacked considering two reviewers that performed eligibility assessment independently and disagreements between those were resolved by consensus; all participants confirmed the process for data acquisitions. For point b), we examined results from the available studies for clues that suggest there may be missing studies (namely publication bias) or missing data from the included studies (namely selective reporting bias).

Statistical analysis
--------------------

All *CDH1*germline mutations were stored in a database, considering the respective geographical origins. Qualitative data in the 2 groups were expressed as frequencies, organized into contingency tables, and evaluated with the \[chi\]^2^test (Pearson \[chi\]^2^test or Fisher exact test) to investigate potential differences. The results were considered statistically significant for *p*\< 0.05. Statistical analysis was conducted by using SPSS statistical package (version 15.0) (SPSS, Chicago, IL).

Results
=======

The majority of selected studies were original reports
------------------------------------------------------

We analysed a total of 212 studies; in detail 156 were excluded because they comprised somatic mutations, germline mutations in breast or colon cancers, molecular analyses, prophylactic gastrectomy descriptions and outdated reviews. Instead, the other 56 studies were included and classified as shown in the flow diagram (Figure [1](#F1){ref-type="fig"}). The majority of the studies were original reports (71.4%), and only the three (5.4%) latest updated reviews were considered for this study \[[@B4],[@B5],[@B54]\]. Two studies (3.6%) were the results of International Workshop Consensus Conferences (namely IGCLC), which delineated the clinical criteria selecting proband for the *CDH1*genetic screening \[[@B2],[@B3]\].

For each included study, we considered the number and the pattern of the identified *CDH1*germline mutations; moreover, we carefully evaluated the ancestry of mutation carriers.

Selection of countries with different risk area for gastric carcinoma
---------------------------------------------------------------------

Far and Middle Western, European and American countries performed almost an independent genetic screening aiming for *CDH1*germline mutation search (Figure [2](#F2){ref-type="fig"}). The countries that identified at least one germline *CDH1*alteration were the following, a) Far East: China, Korea, Japan and New Zealand; b) Middle East: Iran and Pakistan; c) Europe: Italy, Spain, Ireland, the United Kingdom, Lithuania, Germany, Finland, the Netherlands, Sweden, Portugal and Austria; d) America: USA, Canada and Colombia.

![**Worldwide map with the overall *CDH1*germilne mutations identified in the different countries**. Red and yellow indicate respectively middle/high- and low- risk area for gastric cancer development.](1471-2407-12-8-2){#F2}

We assembled these countries considering the incidence rates of gastric carcinoma spread and were classified as: a) low- (group A) and b) middle/high-risk (group B) area (details are described in method section).

Frequency of CDH1 mutation is associated with specific gastric cancer risk area
-------------------------------------------------------------------------------

All genetic screenings identified at least 122 *CDH1*germline mutations (Table [1](#T1){ref-type="table"}); 72.1% of these were non-missense and 27.9% missense alterations (Table [2](#T2){ref-type="table"}). Non-missense mutations occurred with a frequency of 87.5% and 5.7%, respectively in groups A and B and missense alterations were 50% in group A and 32.4% in group B (Figure [3](#F3){ref-type="fig"}). Twelve *CDH1*mutations, six non-missense and six missense, were reported without ancestry. 93 *CDH1*germline mutations were identified in group A; 17 (18.3%) were missense and 77 (82.7%) non-missense. In group B, a total of 16 germline mutations have been reported, from which 11 (68.7%) were missense and 5 (31.3%) non-missense. The overall *CDH1*germline mutation frequency was significantly higher in group A as well as the rate of non-missense alterations (group A vs. group B: Fisher exact test χ^2^15,872; *p*\< 0.001).

###### 

Frequencies of missense and non-missense *CDH1*germline mutations in group A and B; statistical analysis reveals a strong association between high *CDH1*mutation frequency with low-risk area for gastric cancer

                                 Missense mutations (%)   Non-missense mutations (%)
  ------------------------------ ------------------------ ----------------------------
  **Low Incidence (group A)**    17 (50)                  77 (87.5)
  **High Incidence (group B)**   11 (32.4)                5 (5.7)
  **Unknown**                    6 (17.6)                 6 (6.8)
  **Total**                      34 (27.9)                88 (72.1)

![**The figure shows the distribution of missense and non-missense *CDH1*germline mutations in low-risk area (group A) and high-risk area (group B)**. Ancestry information of group C is unknown.](1471-2407-12-8-3){#F3}

Minimization of risk bias
-------------------------

Point a) Two independent reviewers confirmed the results crosschecking all data, as well as the number and the ethnicity of *CDH1*germline mutations; results were routinely discussed in scientific meetings and seminars. To facilitate the common consultation, all identified *CDH1*alterations were recorded in Table [1](#T1){ref-type="table"}. Point b) The heterogeneity of publications could be a risk bias; we considered only original reports that were the large majority of the analysed paper (71.4%), and reviews as other papers were considered only to confirm the results from those original reports. In particular, the last review \[[@B5]\] and one original paper \[[@B18]\] reported some *CDH1*germline mutations namely as \"unpublished results\", this could reduce the risk bias related with the \"missing studies\". Considering the \"selective reporting bias\" as the missing data from the included studies, we assessed that the *CDH1*mutations overlapped with the latest review \[[@B5]\] and with the selected original papers.

Discussion
==========

Incidence of gastric carcinoma
------------------------------

Until recently, gastric carcinoma was the second most common cancer worldwide, but now, with an estimated 934,000 new cases per year in 2002 (8.6% of new cases), it is in fourth place behind cancers of lung, breast and colon and rectum. It is the second most common cause of cancer death (700,000 deaths annually). Almost two-thirds of cases occur in developing countries and 42% in China alone. The geographic distribution of GC is characterized by wide international variations; high-risk areas include East Asia (China, Japan and Korea), Eastern Europe, and parts of Central and South America. Incidence rates are low (\< 10 per 100,000 in men) in Southern Asia, North and East Africa, North America, Australia, New Zealand and Africa \[[@B17],[@B55]\].

In Europe, GC represents the fifth most common cancer, after colon and rectum, breast, lung and prostate, with an incidence of 149,000 per year and mortality rate of 116,000. The highest European risk area for GC is the Eastern zone with an incidence of 70,000 per year (Belarus area). Portugal and Italy represent one of the most high-risk European areas for stomach cancer, in particular, respectively, with incidence in 2008 of 41,100 and in Italy with incidence of 33,400 per year \[[@B17]\]. In Italy, Tuscany and central regions present a GC mortality rate of 4,2/10,000 inhabitants (2002 ISTAT-*The Italian National Institute of Statistics*).

E-cadherin and diffuse gastric cancer
-------------------------------------

The *CDH1*gene maps to chromosome 16q22.1 and consists of 16 exons that encode a 120-kDa protein called E-cadherin, which is a member of the transmembrane glycoproteins family. E-cadherin is expressed on epithelial tissues and is responsible for calcium-dependent cell-cell adhesion. Functionally, it is critical for establishing and maintaining polarized and differentiated epithelia through intercellular adhesion complexes. Human E-cadherin is considered an invasion suppressor, and under-expression of E-cadherin is correlated with the infiltrative and metastatic ability of the tumor \[[@B6]\].

In 1998 in New Zealand, a country that represents a low GC risk-area, Guilford and Colleagues identified firstly in Maori kindred the first *CDH1*germline truncating mutation in cases with family history for diffuse gastric carcinoma \[[@B1]\]. Subsequently, several international countries reported other *CDH1*germline mutations in HDGC or in sporadic EODGC with different ethnicities \[[@B4],[@B54]\].

The definition of the HDGC syndrome was established in 1999 by the IGCLC that also delineated the criteria for the *CDH1*genetic screening, as follows: 1) two or more documented cases of diffuse gastric cancer in 1st/2nd degree relatives, with at least one diagnosed before the age of 50, or 2) three or more cases of documented diffuse gastric cancer in 1st/2nd degree relatives, independently of age of onset \[[@B2]\]. Subsequently, the last consensus conference of Cambridge in 2010 \[[@B3]\], modified the criteria as: a) two GC cases in family, one confirmed DGC \< 50; b) three confirmed DGC cases in 1st or 2nd degree relatives independent of age; c) age \< 40; Corso and Colleagues recently proposed the cut-off age of onset at ≤ 35 in sporadic EODGC \[[@B4]\]; d) personal or family history of DGC and lobular breast cancer, one \< 50.

In this study, we reported a total of 122 *CDH1*germline mutations, respectively 94 (77%) in group A (low-risk area) and 16 (13.1%) in group B (middle/high-risk area) (12-9.9% mutations were without ethnicity information).

Revising these 122 *CDH1*mutations, we observed some main findings: 1) the overall mutation rate is lower in group B rather than in group A (13.1% vs. 77%; *p*\< 0.001); 2) group A shows a higher frequency of non-missense mutations; moreover, *CDH1*non-missense mutations are extremely lower in group B (5.7%), in which missense variants are predominant (32.4%) (Figure [2](#F2){ref-type="fig"}).

Considering the first point, we stated that *CDH1*germline mutations in GC middle/high-risk area are rather rarely identified respecting to low-risk area; as reported, in middle/high-risk area the probability to perform a *CDH1*genetic screening with negative result is high enough \[[@B10]-[@B12]\], in which maybe operates environmental factors.

Summary of evidence: CDH1 mutations and geographic variability
--------------------------------------------------------------

The abovementioned clinical criteria represents an important approach in selecting probands for the *CDH1*genetic screening. Currently, different modifications have been appointed at these criteria \[[@B2],[@B4],[@B33]\], evaluating clinical and molecular results along the international consensus conferences; so far, the risk area vs. incidence of gastric carcinoma has never been discussed in these scientific meetings. We stated that \"GC risk area and incidence\" can represent an important emerging factor that relates strongly to the prognosis and other important behaviors of GC patients; ethnicity of GC patients coming from low- or high-risk areas could be considered in these criteria in order to identify cases with high or low-risk mutation carriers in hereditary syndromes. Information about the ancestry, can improve the accuracy of proband selection for the *CDH1*genetic screening; in particular, we can consider GC patients as high or low-risk mutation carriers respectively in low or high-risk GC areas whenever the abovementioned criteria is fulfilled. This data verifies that in high-risk areas, clinical criteria should be applied strictly to cases with a strong family history for GC in particular when it has identified very young members.

It is important to stress that geographical variability represents a novel risk factor for gastric carcinoma, clinico-pathological features and some molecular results can confirm it. These acknowledgments, like the GC risk-area, provide important information and can propose different approaches in clinical practice for GC prevention and treatment.

Molecular features and pathogenicity of E-cadherin missense mutations
---------------------------------------------------------------------

The second consideration of this study is that GC high-risk area shows a higher frequency of *CDH1*missense mutations; identification of a *CDH1*missense alteration also implicated its functional assessment, because *in vitro*and *in silico*analysis with study of control population demonstrates that this mutation can be a novel polymorphic variant without pathogenic impact. We also revised the frequencies of *CDH1*germline missense mutations with a pathogenic role that was assessed in 21 *CDH1*missense alterations \[[@B4],[@B56]\]; 17 of these showed a deleterious impact and respectively 5 (29.4%) were coming from middle/high risk-areas and 12 (70.6%) from low risk-areas. The pathogenicity of the remaining 13 mutations is unknown. As reported, the probability of finding a novel pathogenic *CDH1*missense mutation (including also non-missense mutations) is higher in GC low-risk areas. Very recently, we revised the role of the *CDH1*germline mutation in pathogenesis of sporadic EODGC; a total of 19 mutations have been reported to date in this GC group but only six (2.3%) of them did in fact represent variants with a proven potentially deleterious effect. This predicted pathogenicity was based on the type of mutation (frameshift) or on the results obtained from in vitro functional analysis. Five of the six germline pathogenic *CDH1*mutations were detected in EOGC patients from low or moderate incidence GC areas, whereas only one arose in a patient from Portugal, a high incidence GC area. Although *CDH1*germline mutations have been searched for in EOGC patients from other areas where high incidence rates of GC are verified, namely in countries like China, Korea, Japan, and even Italy, no deleterious *CDH1*germline variants have been identified \[[@B4]\].

These results demonstrated that functional assessment of *CDH1*germline missense mutations is mandatory, in particular in GC high-risk cases that show a higher frequency of unpathogenic missense mutations.

Limitations of the current study
--------------------------------

Certainly, this study presents some limitations that should be discussed, also for further consideration. First, the *CDH1*germline mutation frequency could be affected by research activity, as publication bias or access to medical care, considering that some *CDH1*variants could be unpublished in MEDLINE; this factor probably is due to the lack of a *CDH1*recorded mutation database. However, MEDLINE is the unique search engine in which we can access easily and freely; unfortunately we do not have access in confidential and in unpublished data. However, this bias should be very small, because we carefully collected all *CDH1*mutations recorded in MEDLINE; we also discussed this point in the \"result\" section. The second point is that we do not know precisely in what proportion of cases *CDH1*mutations are identified in low vs. middle/high risk areas, and if the mutation frequency is related to the number of screened subjects; moreover, the accuracy of this study could be affected by the human migrations. The overall *CDH1*mutation number identified to date is rather low and we are not able to also include this factor (as ratio between number of mutations vs. number of screened kindred, migration of population, etc.) risking to dissipate the statistical value, in the excess of data stratification. In the specific, we were not able to assess the quantitative genetic analysis due to the lack of information about the impact of environmental factor in DGC development and about migratory behavior. Further, if applicable and also considering that the clinical criteria are rather limited, in a larger family collection, this data could be considered. The third limitation is that we cannot analyse intestinal GC and other risk factors, such as environmental agents (i.e. specific diet habits); however, the aim of this study is only to assess the frequency of *CDH1*germline mutation in DGC, in which environmental factors are probably less important than in intestinal hystotype. Moreover, the *CDH1*germline or somatic mutations have not reported in intestinal gastric carcinoma, and for this reason, it was excluded from this systematic review.

Conclusion
==========

GC patients coming from high-risk areas show a lower incidence of *CDH1*germline mutations when compared with individuals coming from low-risk areas. The finding that *CDH1*mutation frequencies are extremely different in high and low-risk GC zones confirms that gastric carcinoma presents various clinico-pathologic and molecular features. This data could also open new different approaches in the GC prevention test; before proposing a proband candidate for the *CDH1*, genetic screening, geographic variability and family history should be considered.
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